ST
Synapse TeamOct 21
Statin plus ezetimibe from the start, or statin first and add later? If eZ-PAVE favours combination therapy in ASCVD, does upfront combination become your default?
What happened
Trial evaluates statin-ezetimibe combination vs statin monotherapy in patients with ASCVD.
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Expert reaction
AHA Scientific Sessions 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward eZ-PAVE's result, from named public quotes (n=0). As of Oct 22, 2026.
Statin-ezetimibe combination therapy versus statin monotherapy in patients with atherosclerotic cardiovascular disease: pre-specified second randomization of the eZ-PAVE trial
Statin-ezetimibe combination therapy versus statin monotherapy in patients with atherosclerotic cardiovascular disease: pre-specified second randomization of the eZ-PAVE trial. Session: LBS.03. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
Ahn et al. (2026) studied this question. Statin-ezetimibe combination therapy versus statin monotherapy is being evaluated in patients with atherosclerotic cardiovascular disease in the eZ-PAVE trial, with results pending.